DVL3 and prostate carcinoma: Vincent C Pai et al. found that the expression of ASPM (a novel Wnt coactivator) was progressively up-regulated in primary and metastatic prostate cancer and that ASPM interacted with Dvl-3 to inhibit the enzymesome-dependent degradation and to increase the protein stability of Dvl-3, which enhances Wnt-induced β-catenin transcriptional activity thereby contributing to the development of prostate cancer (Pai et al. 2019).